Karyopharm Therapeutics files Chapter 11 and plans merger with Ayrmid
Karyopharm Therapeutics filed voluntary Chapter 11 petitions and announced a plan to merge with Ayrmid Ltd., the parent of Gamida Cell. The company secured up to $55 million of debtor‑in‑possession financing to fund operations during the restructuring. The court‑supervised sale process is slated to close in the first quarter of 2027, subject to court approval and possible competing bids. Karyopharm will keep its XPOVIO sales and development programs running while the transaction proceeds.
Why it matters
The DIP loan will fund Karyopharm’s ongoing business and meet its obligations through the bankruptcy (the company says). Existing equity holders are expected to receive no value, so the merger determines the future upside for creditors and Ayrmid.
Key facts
- 1Karyopharm filed voluntary Chapter 11 petitions in the Southern District of Texas. prnewswire.com
- 2Ayrmid Ltd. is named the lead bidder in the court‑supervised sale process. stocktitan.net
- 3The company obtained commitments for up to $55 million of debtor‑in‑possession financing. prnewswire.com
- 4The transaction is planned to close in the first quarter of 2027, pending court approval and possible competing bids. prnewswire.com
- 5Karyopharm reported $115 million in XPOVIO sales, a $196 million loss, and a $1.8 billion accumulated deficit. finance.yahoo.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.